Statins may hold the answer to slowing the deterioration of patients with multiple sclerosis (MS), scientists have said.
In a new trial hailed as “highly promising”, patients who took the daily pill retained their coordination better and suffered less brain shrinkage than those given a placebo.
It raises the prospect that MS sufferers, of whom there are more than 90,000 in the UK, may be prescribed the common cholesterol-busting drug to improve their symptoms.
Deep brain stimulation (DBS), an experimental technology that involves implanting a pacemaker-like device in a patient’s brain to send electrical impulses, is a hotly debated subject in the field of medicine. It’s an inherently risky procedure and the exact effects on the human brain aren’t yet fully understood.
But some practitioners believe it could be a way to alleviate the symptoms of depression or even help treat Alzheimer’s — and now they suspect it could help with drug addiction as well.
In a world’s first, according to the Associated Press, a patient in Shanghai’s Ruijin Hospital had a DBS device implanted in his brain to treat his addiction to methamphetamine.
Neuroleptic malignant syndrome (NMS) is rare but one of the most serious adverse effects of antipsychotics. Here, we report a case of risperidone-associated NMS in which a successful rechallenge of risperidone was observed with a positive follow-up. A 47-year-old female with schizophrenia was treated with risperidone 4 mg/d for 8 months in 2009 and was admitted to our hospital in 2015 owing to violent behavior under persecutory delusions. Risperidone 2 mg/d was initiated and increased to 4 mg/d 54 days later. Further, long-acting injectable (LAI) risperidone 25 mg per 2 weeks was added on hospital day 15. On hospital day 116, NMS occurred and thus we discontinued all antipsychotics including LAI risperidone, then NMS improved. We resumed LAI risperidone 25 mg per 2 weeks on hospital day 148, thus we waited for 22 days before re-starting the drug treatment. She was discharged on hospital day 371, then switched to LAI paliperidone 150 mg per 4 weeks 2 months later. At the time of a follow-up 3 years later, NMS had not reoccurred. This case reports on an unusual presentation of NMS in which no hyperthermia was observed. Furthermore, this case indicated that NMS may occur in a dose-dependent manner. In conclusion, this case reported important information for clinicians with regard to antipsychotic drug rechallenges and proper dosing of APs to avoid or reverse NMS.
A 47-year-old female with schizophrenia and without other neuropsychiatric or systemic illnesses was treated with risperidone 4 mg/d for 8 months in 2009. In 2015, she was admitted owing to the violent behavior of attacking her mother-in-law under persecutory delusion with the belief that her mother-in-law was going to murder her and auditory hallucination of hearing her mother-in-law criticize her behind her back. Risperidone 2 mg/d was initiated and increased to 4 mg/d 54 days later. Further, long-acting injectable (LAI) risperidone 25 mg per 2 weeks was added on hospital day 15. She did not receive any mood stabilizers on admission, such as lithium, carbamazepine, valproate. During treatment, the patient complained of soreness and weakness of her whole body, and refused to eat or ambulate on hospital day 116, at which point she was tachycardic with a bpm of 116, but afebrile (36.4°C) with stable blood pressure (113÷72 mm Hg).
A study out of John’s Hopkins University published by Dr. Robert Yolken, MD, and colleagues late last year have found a possible biomarker for schizophrenia. Biomarkers are extremely important to help diagnose disease, yet very few exist for psychiatric disorders. You cannot take a blood test to diagnose depression, for example. The current study found that schizophrenics carry a high level of a certain antibody produced in response to Epstein–Barr virus (EBV), a type of herpes virus that can lead to infectious mononucleosis (aka “mono” or “the kissing disease”). The schizophrenic patients in this study had a greater immune response to EBV-viral capsid antibody (VCA) compared to controls.
Depending on who you talk to, everything is either fine, or we’re living in an oppressive cyberpunk dystopia in which we forgot to drench everything in colored neon lighting. There’s little to be done about the digital surveillance panopticon that stalks our every move, but as far as the aesthetic goes, [abetusk] is bringing the goods. The latest is a laser jacket, to give you that 2087 look in 2019.
The build starts with a leather jacket, which is festooned with 128 individual red laser diodes. These are ganged up in groups of 4, and controlled with 32 individual PWM channels using two PCA9685 controllers. An Arduino Nano acts as the brains of the operation, receiving input from a joystick and a microphone. This allows the user to control lighting effects and set the jacket to respond to sounds and music.
[abetusk] does a great job of conveying the tricks needed to successfully pull this off. The instructions should allow any curious maker to replicate the build at home, and code is available on Github to help run the show. There’s lots of detail on proper enclosures, connectors, and cabling techniques to avoid the wearer inadvertently pulling everything to bits when wearing the garment to the club. Remember, there’s nothing more punk than educating your friends.
Longevity technology number one, according to the Longevity Impact Forum rating, proven by Patient zero.
Liz Parrish, CEO of BioViva USAa short clip from her gene therapy that she took in 2015 against biological aging. This is the first step to curing diseases like Alzheimer’s disease, heart disease, kidney failure and cancer. If we work toward this goal quickly we could save almost 8 billion people from inhumane and expensive deaths.
https://www.BioViva-Science.com
https://www.Integrated-Health-Systems.com
Engage with us; Like, Follow, Share, Subscribe, Comment:
https://www.linkedin.com/in/liz-parrish-73870629/
https://www.facebook.com/BiovivaSciences/
Tweets by BioVivaScience
https://www.instagram.com/biovivasciences/
#disruptaging #genetherapy #genomiccounseling #biovivascience #genome #senescence #aging #longevity
Biomedical application of quercetin (QT) as an effective flavonoid has limitations due to its low bioavailability. Superparamagnetic iron oxide nanoparticle (SPION) is a novel drug delivery system that enhances the bioavailability of quercetin. The effect of short time usage of quercetin on learning and memory function and its signaling pathways in the healthy rat is not well understood. The aim of this study was to investigate the effect of free quercetin and in conjugation with SPION on learning and memory in healthy rats and to find quercetin target proteins involved in learning and memory using Morris water maze (MWM) and computational methods respectively. Results of MWM show an improvement in learning and memory of rats treated with either quercetin or QT-SPION. Better learning and memory functions using QT-SPION reveal increased bioavailability of quercetin. Comparative molecular docking studies show the better binding affinity of quercetin to RSK2, MSK1, CytC, Cdc42, Apaf1, FADD, CRK proteins. Quercetin in comparison to specific inhibitors of each protein also demonstrates a better QT binding affinity. This suggests that quercetin binds to proteins leading to prevent neural cell apoptosis and improves learning and memory. Therefore, SPIONs could increase the bioavailability of quercetin and by this way improve learning and memory.
